Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
76 hedge funds and large institutions have $150M invested in Adaptimmune Therapeutics in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 21 reducing their positions, and 11 closing their positions.
277% more call options, than puts
Call options by funds: $132K | Put options by funds: $35K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.91% less ownership
Funds ownership: 10.94% → 10.04% (-0.91%)
5% less funds holding
Funds holding: 80 → 76 (-4)
19% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 21
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
41% less capital invested
Capital invested by funds: $256M → $150M (-$106M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$1.82M |
| 2 |
Renaissance Technologies
New York
|
+$433K |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$329K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$204K |
| 5 |
JP Morgan Chase
New York
|
+$134K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$9.27M |
| 2 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$1.07M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$793K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$585K |
| 5 |
HCA
Harbor Capital Advisors
Chicago,
Illinois
|
-$297K |
ADAP Hedge Fund Activity: Q2 2024 in Review
76 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q2 2024, worth a combined $150M — down 41% from $256M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ADAP and 7 opened new positions — a net loss of 4 holders — while 21 trimmed existing stakes and 17 added.
The largest buyer was Long Focus Capital Management, adding an estimated $1.82M. The largest seller was Baker Bros. Advisors, cutting an estimated $9.27M.
- 76 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q2 2024, down from 80 in Q1 2024.
- Funds reported $150M of Adaptimmune Therapeutics stock for Q2 2024, down 41% quarter-over-quarter.
- 7 funds opened new Adaptimmune Therapeutics positions in Q2 2024 and 11 closed out, a net change of -4 holders.
- The largest Adaptimmune Therapeutics buyer in Q2 2024 was Long Focus Capital Management, an estimated $1.82M added.
- The largest Adaptimmune Therapeutics seller in Q2 2024 was Baker Bros. Advisors, an estimated $9.27M sold.
Based on aggregated 13F filings for Q2 2024.